May 17, 2026 16:00 ET | Source: Design Therapeutics, Inc. CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics,…
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep…
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect…
– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed…
100% of patients treated with CTA313 achieved an SRI-4 response, with half achieving remission May 14, 2026 11:43 ET |…
Longitudinal analysis reveals clear gaps in global preparedness against emerging viral threats and future pandemics.CAMBRIDGE, Mass., May 12, 2026 /PRNewswire/…
Acquisition also strengthens telecommunications expertise and accelerates global growthFRISCO, Texas and LONDON, May 12, 2026 /PRNewswire/ -- Bounteous, an AI…
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events…
BASEL, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system…
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular…